Oppenheimer & Co’s Pulse Biosciences PLSE Stock Holding History

Oppenheimer & Co’s Portfolio PLSE Stock Details PLSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,850	Closed	-$176K	–	1771
2025 Q4	$176K	Hold	12,850	–	–	﹤0.01%	1452
2025 Q3	$227K	Hold	12,850	–	–	﹤0.01%	1494
2025 Q2	$194K	Hold	12,850	–	–	﹤0.01%	1510
2025 Q1	$207K	Sell	12,850 -5,000	-28%	-$93.2K	﹤0.01%	1446
2024 Q4	$311K	Buy	+17,850	New	+$315K	﹤0.01%	1247

Other funds holding PLSE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Oppenheimer & Co's PLSE Position: Q1 2026 in Review

Oppenheimer & Co sold out of Pulse Biosciences (PLSE) in Q1 2026, closing a stake of 12,850 shares — an estimated $176K sold.

Oppenheimer & Co first reported a position in PLSE in Q4 2024 and held it in 5 quarters. The position peaked at $311K in Q4 2024. 96 funds tracked by Wall St. Rank hold PLSE as of Q1 2026.

Oppenheimer & Co reported no remaining Pulse Biosciences position as of Q1 2026 after selling out during the quarter.
Oppenheimer & Co sold 12,850 Pulse Biosciences shares in Q1 2026, an estimated $176K.
Oppenheimer & Co first reported a position in Pulse Biosciences in Q4 2024 and held it in 5 quarters.
Oppenheimer & Co's Pulse Biosciences position peaked at $311K in Q4 2024.
96 funds tracked by Wall St. Rank held Pulse Biosciences as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.